Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The role of dextromethorphan in pain control
Autore:
Weinbroum, AA; Rudick, V; Paret, G; Ben-Abraham, R;
Indirizzi:
Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Post AnesthesiaCare Unit, IL-64239 Tel Aviv, Israel Tel Aviv Univ Tel Aviv Israel IL-64239 e Unit, IL-64239 Tel Aviv, Israel Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Anesthesiol & Crit Care, IL-64239 Tel Aviv, Israel Tel Aviv Univ Tel Aviv Israel IL-64239 t Care, IL-64239 Tel Aviv, Israel Tel Aviv Univ, Sackler Fac Med, Chaim Sheba Med Ctr, Pediat Intens Care Unit, IL-64239 Tel Aviv, Israel Tel Aviv Univ Tel Aviv Israel IL-64239 e Unit, IL-64239 Tel Aviv, Israel
Titolo Testata:
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
fascicolo: 6, volume: 47, anno: 2000,
pagine: 585 - 596
SICI:
0832-610X(200006)47:6<585:TRODIP>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
NMDA RECEPTOR ANTAGONIST; DECREASES POSTOPERATIVE PAIN; AMINO-ACID ANTAGONISTS; ORAL DEXTROMETHORPHAN; DOUBLE-BLIND; POSTHERPETIC NEURALGIA; DIABETIC NEUROPATHY; CANCER PAIN; DORSAL HORN; SECONDARY HYPERALGESIA;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
75
Recensione:
Indirizzi per estratti:
Indirizzo: Weinbroum, AA Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Post AnesthesiaCare Unit, 6 Weizman St, IL-64239 Tel Aviv, Israel Tel Aviv Univ 6 Weizman St Tel Aviv Israel IL-64239 Israel
Citazione:
A.A. Weinbroum et al., "The role of dextromethorphan in pain control", CAN J ANAES, 47(6), 2000, pp. 585-596

Abstract

Purpose: To review the clinical benefits of dextromethorphan (DM) in pain management, describe its neuropharmacological properties. Source: A Medline search was made for experimental and clinical data on DMuse from 1967 to date using keywords nociception, acute and chronic pain control, N-methyl-D-aspartate, antagonists, dextromethorphan. Principle findings: The 930 DM citations mostly described its antitussive,metabolic and toxicological aspects, animal studies and its possible role in minimizing post-brain ischemia complications in humans. The use of DM inacute pain revealed eight original studies involving 443 patients, as wellas two preliminary reports and our own unpublished data on 513 patients. Most of the 956 patients had general anesthesia. Eight studies (154 patients) and one case report dealt with chronic pain management. This N-methyl-D-aspartate (NMDA) receptor antagonist binds to receptor sites in the spinal cord and central nervous system, thereby blocking the generation of central acute and chronic pain sensations arising from peripheral nociceptive stimuli and enabling reduction in the amount of analgesics required for pain control. DM attenuated the sensation of acute pain at doses of 30-90 mg, without major side effects, and reduced the amount of analgesics in 73% of the postoperative DM-treated patients, Studies in secondary pain models in healthy volunteers and in various types of chronic pain showed DM to be associated with unsatisfactory pain relief. Conclusion: DM attenuates acute pain sensation with tolerable side effects. Its availability in oral form bestow advantages over other NMDA antagonists.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 03:46:14